Novel therapeutics in colorectal cancer

Dis Colon Rectum. 2005 Aug;48(8):1632-50. doi: 10.1007/s10350-005-0026-8.

Abstract

Colorectal cancer is an excellent tumor model for evaluating novel therapeutic strategies. Development of a mechanistic understanding of how this cancer develops, spreads, and grows allows a tailored approach to all stages of treatment: prevention, adjuvant treatment, and therapy of advanced disease. We focus on therapy in the advanced disease setting, although progress in this area could lend itself to treatment of early or premalignant disease. In the last 20 years, information has been generated about the intracellular pathways of tumor formation, invasion, and metastasis. As a result, specific molecular processes have been targeted for therapeutic intervention, including cell surface growth factor receptors, proliferation signaling, cell cycling, apo-ptosis, angiogenesis, and matrix metalloproteinases. We review the scientific rationale for recently developed novel therapeutics in colorectal cancer, and the results of clinical trials to date. We also suggest appropriate clinical settings for specific targets and outline future directions of research.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis
  • Cell Cycle
  • Colonic Neoplasms / drug therapy*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Growth Substances / therapeutic use
  • Humans
  • Intracellular Signaling Peptides and Proteins / therapeutic use
  • Receptors, Growth Factor / therapeutic use
  • Rectal Neoplasms / drug therapy*
  • Tissue Inhibitor of Metalloproteinases / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Cyclooxygenase Inhibitors
  • Growth Substances
  • Intracellular Signaling Peptides and Proteins
  • Receptors, Growth Factor
  • Tissue Inhibitor of Metalloproteinases